This article was originally published in The Tan Sheet
OTCs comprised 33% of osteoporosis treatments purchased during 12 months ended June 30, a consumer survey conducted by NPD PharmTrends shows. Overall, 7% of U.S. consumers use drugs or supplements to treat and prevent osteoporosis, up from 4% in prior-year period. Dollar share for calcium supplements - including Mission Pharmacal's Citracal, Whitehall-Robins' Caltrate and SmithKline Beecham's Oscal brands - totals 5.1%, compared to 82% for top five Rx drugs, PharmTrends notes. Information Resources, Inc. (Chicago) lists total food, drug and mass calcium sales at $361.5 mil. for the 52 weeks ended Nov. 12
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC